Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study.

摘要: BACKGROUND The objective of the current study was to define activity and tolerability, as well influence on resectability, combination gemcitabine, paclitaxel, cisplatin (GTP) induction chemotherapy for patients with Stage IIIA(N2) nonsmall cell lung carcinoma (NSCLC). METHODS Forty-nine chemotherapy-naive (median age, 61 years; World Health Organization performance status, 0–1) biopsy-proven disease received 1000 mg/m2 125 50 Days 1 8 every 3 weeks until reevaluation surgery or definitive radiotherapy. RESULTS Grade 3–4 neutropenia most common hematologic toxicity, occurring in 32.7% patients; however, only case febrile reported. Grade thrombocytopenia occurred 12.2% but not associated bleeding. Severe nonhematologic toxicities were uncommon; 4 toxicity diarrhea, which 4% patients. One patient died after first course therapy, this event found be unrelated treatment. Thirty-six (73.5%) achieved an response, additional had stable clearance mediastinal lymph nodes. Overall, 29 underwent thoracotomy 27 (55%) complete resection. Mediastinal nodes free tumor 35% all cases, pathologic responses (16%) Median survival 23 months, a 1-year rate 85%. CONCLUSIONS GTP is highly active regimen NSCLC yields good results. The use GTP radiotherapy new biologic drugs should explored. Cancer 2003. © 2003 American Society. DOI 10.1002/cncr.11662